Edition:
India

Freeport-McMoRan Inc (FCX.N)

FCX.N on New York Stock Exchange

18.73USD
16 Feb 2018
Change (% chg)

$-0.39 (-2.04%)
Prev Close
$19.12
Open
$19.04
Day's High
$19.26
Day's Low
$18.66
Volume
5,433,959
Avg. Vol
4,947,762
52-wk High
$20.24
52-wk Low
$11.05

Select another date:

Mon, Feb 19 2018

Indonesia hands Freeport, Amman, quota for 2018 copper exports

* Indonesia issued the local unit of copper miner Freeport McMoRan Inc with a quota to export 1,247,866 wet metric tonnes (wmt) of copper concentrate up to Feb 15, 2019, a mining ministry official said on Monday.

BRIEF-Carl Icahn Now Owns 4.14 Pct Stake In Freeport-McMoRan

* CARL ICAHN SAYS NOW OWNS 4.14 PERCENT STAKE IN FREEPORT-MCMORAN INC AS OF FEB 14 - SEC FILING

Indonesia 'still evaluating' extension of Freeport copper exports -official

* Indonesia is 'still evaluating' a proposed extension of copper concentrate exports by local unit of Freeport McMoRan Inc , a mining ministry official said on Thursday.

Copper miner Freeport-McMoRan reinstates dividend on stronger outlook

Feb 6 Freeport-McMoRan Inc reinstated its cash dividend on Tuesday, three years after suspending it, reflecting a stronger financial position, improved market conditions and a positive outlook for cash generation.

BRIEF-Freeport-McMoRan Reinstates Cash Dividend On Common Stock

* FREEPORT-MCMORAN REINSTATES CASH DIVIDEND ON COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Fibrocell Science Says‍ Expect To Initiate A Safety Clinical Trial In 2018 For Fcx-013 Development

* FIBROCELL SCIENCE SAYS‍ EXPECT TO INITIATE A SAFETY CLINICAL TRIAL IN 2018 FOR FCX-013 DEVELOPMENT - SEC FILING​ Source text for Eikon: Further company coverage:

BRIEF-Fibrocell Science Says Submitted IND Application For FCX-013 To Treat Type Of Skin Disorder

* FIBROCELL SCIENCE SAYS SUBMITTED INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA​ Source text for Eikon: Further company coverage:

BRIEF-Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007

* FIBROCELL ANNOUNCES FDA ALLOWANCE TO INITIATE PEDIATRIC ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL OF FCX-007 FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB)

UPDATE 3-Freeport points to progress in Indonesia permit talks

* No formal deal on Grasberg copper mine, but talks positive - CEO

BRIEF-Freeport makes progress in Indonesia permit talks - CEO Adkerson

* SIGNED NEW 2-YEAR LABOR DEAL IN INDONESIA IN DECEMBER - CHIEF EXECUTIVE ADKERSON

Select another date: